Immunotherapy of metastatic renal cell carcinoma

Cancer

Volumn 115, Issue SUPPL. 10, 2009, Pages 2298-2305

  McDermott, David F ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

Carbonic anhydrase IX; Immunotherapy; Interferon ; Interleukin 2; Renal cancer

Indexed keywords

ALPHA INTERFERON; AP 12009; BEVACIZUMAB; BMS 663513; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; GC 1008; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYB 2055; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; IPILIMUMAB; MDX 1106; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH ANTIBODY; SORAFENIB; SUNITINIB; TOLL LIKE RECEPTOR AGONIST; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; ENTERITIS; HAND FOOT SYNDROME; HUMAN; HYPOPHYSITIS; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 65949102289     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24236     Document Type: Conference Paper

References (58)

1. Gleave ME, Ehilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998;338:1265-1271.
2. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63:128-131.
3. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol. 1992;148:1247-1248.
4. Marten A, Flieger D, Renoth S, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother. 2002;51:637-644.
5. Chang AE, Li Q, Jiang G, et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003;21:884-890.
6. McDermott DF, Rini BI. Immunotherapy for metastatic renal cell carcinoma. Br J Urol. 2007;99:1282-1288.
7. Gitlitz BJ, Belldegrun AS, Figlin RA. Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol. 2001;19:141-147.
8. Lesimple T, Moison A, Guille F, et al. Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J Immunother. 2000;23:675-679.
9. Schwabb T, Heaney JA, Schned AR, et al. A randomized phase II trial comparing 2 different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol. 2000;163:1322-1327.
10. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
11. Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J Sci Am. 2002;8:2-11.
12. Rini BI, Zimmerman T, Stadler WM, et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002;20:2017-2024.
13. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med. 1985;161:1169-1188. (Pubitemid 15011332)
14. Mule JJ, Yang JC, Lafreniere RL, et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol. 1987;139:285-1194
15. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
16. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
17. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007;356:2271-2281.
18. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007;370:2103-2111.
19. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
20. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6:S55-S57.
21. Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228:307-319.
22. Belldegrun A, Webb DE, Austin HA III, et al. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol. 1989;141:499-503.
23. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7:486-498.
24. Neidhart JA. Interferon therapy for the treatment of renal cancer. Cancer. 1986;57:1696-1699.
25. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol. 1987;14:36-42.
26. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006;24:5584-5592.
27. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of 2 routes of administration. J Clin Oncol. 1987;5:286-291.
28. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol. 2000;18:4009-4015. (Pubitemid 32038392)
29. Medical Research Council and Collaborators. Interferon alfa and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14-17.
30. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859-2867. (Pubitemid 29415245)
31. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer [serial online]. Cochrane Database Syst Rev. 2005;(1):CD001425.
32. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272-1278. (Pubitemid 28216581)
33. Yang JC, Sherry RM, Stienberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132. (Pubitemid 46606294)
34. McDermott DF, Regan MM, Clark JI, et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141. (Pubitemid 41702632)
35. Negrier S, Perol D, Ravaud C, et al. Medroxyprogesterone, interferon alfa-2a, interleukin-2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial. Cancer. 2007;110:2468-2477.
36. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523-528.
37. Motzer RJ, Bacil J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376-2381. (Pubitemid 34441667)
38. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Renal cell carcinoma: histologic predictors of cytokine response. J Immunother. 2005;28:488-495.
39. Grabmaier K, MC AdW, Verhaegh GW, et al. Strict regulation of CAIX (G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene. 2004;23:5624-5631. (Pubitemid 39093040)
40. Bui MHT, Seligson D, Han K, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.
41. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714-3721. (Pubitemid 40685588)
42. Pantuck AJ, Fang Z, Liu X, et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol. 2005;23(16S). Abstract 4535.
43. Jaeger E, Waldman R, Roydasgupta T, et al. Array-based comparative genomic hybridization identifies chromosomal imbalances between interleukin-2 complete and non-responders [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 5043.
44. Schwarzberg T, Regan MM, Liu V, et al. Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 5044.
45. Ernstoff M, Regan MM, McDermott DF, et al. First-line therapy with bevacizumab and high dose bolus aldesleukin (IL-2) in metastatic renal cell carcinoma patients [abstract]. J Clin Oncol. 2007;25(18S). Abstract 15524.
46. Gollob JA, Rathmell WK, Richmond T, et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-alpha2b) as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25:3288-3295. (Pubitemid 47325614)
47. Ryan CW, Goldman BH, Lara J, et al. Sorafenib plus interferon alpha2b (IFN) as first-line therapy for advanced renal cell carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25:3296-3301.
48. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract]. Presented at: ASCO 2008 Genitourinary Cancers Symposium, February 26-28, Orlando, Florida. Abstract 350.
49. Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007;30:749-761. (Pubitemid 47480758)
50. Oosterwijk-Wakka JC, Tiemessen DM, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother. 2002;25:500-508.
51. Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66:5910-5918. (Pubitemid 43927146)
52. Yang JC, Hughes M, Kammula U, et al. Impilimumab (anti-CLTA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-830. (Pubitemid 350295361)
53. Brahmer JR, Topalian S, Wollner I, et al. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 3006.
54. Morris JC, Shapiro GI, Tan AR, et al. Phase I/II study of GC1008: a human anti-transforming growth factor-beta monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 9028.
55. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 3007.
56. Schmidt H, Selby P, Mouritzen U, et al. Subcutaneous dosing of recombinant human interleukin-21 is safe and has clinical activity: results from a dose-escalation study in stage 4 melanoma and renal cell cancer [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 3041.
57. Moore DJ, Hwang J, McGreivy J, et al. Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors [abstract]. J Clin Oncol. 2005;23:(16S; pt I of II). Abstract 2503.
58. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.